Parkinson's Disease in Light of the COVID-19 Pandemic.
Anna Drelich-ZbrojaMateusz ChedaMaryla KuczyńskaIzabela DąbrowskaEwa KopytoIzabela HalczukPublished in: Brain sciences (2022)
In this review we attempt to collate the existing scientific evidence regarding the possible role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the pathophysiology of Parkinson's disease (PD), as well as to investigate the impact of PD/parkinsonism on the clinical course of the viral infection itself. Since etiology of PD is not completely understood, various studies suggest different potential links between coronavirus disease 2019 (COVID-19) and PD. Suggested connections include, among others, similar prodromal symptoms, renin-angiotensin-aldosterone system involvement, or gut microbiome dysbiosis participation. Despite the initial assumptions that, as a mainly elderly population suffering from rigidity of respiratory muscles, impairment of cough reflex, and dyspnea, PD patients would be more susceptible to viral infection, and would experience a more aggressive course of COVID-19, the published scientific reports contain mutually exclusive data that require further investigation and meta-analysis.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- end stage renal disease
- ejection fraction
- angiotensin ii
- parkinson disease
- newly diagnosed
- angiotensin converting enzyme
- emergency department
- prognostic factors
- electronic health record
- risk assessment
- peritoneal dialysis
- drug induced
- adverse drug
- community dwelling